Implant Centre Martinko has been acquired by Adria Dental Group
Adria Dental Group (ADG) has acquired Implant Centre Martinko (ICM) from a private individual who was also its head surgeon. This investment represents a significant strategic move for ADG, marking its entry into the Italian market, strengthening its position in Croatia and opening new opportunities for growth. Both entities will see improvements in patient care quality through this collaboration, and ICM employees will benefit from enhanced working conditions.
ICM is a renowned Croatian dental implant center, with a clinic in Zagreb and two clinics in Milan and Trieste, Italy. It offers a range of services, including dental implantology, prosthetics and conservative and aesthetic dentistry. The company is a pioneer in positioning Croatia as a destination for high-quality dental services in the EU market and beyond.
Adria Dental Group is the largest dental group in the Adriatic region, operating 12 clinics across Croatia and Slovenia, over 150 cutting-edge dental offices and nine high-end laboratories. The group employs over 700 professionals and treats nearly 55,000 patients annually.
Provectus Capital Partners (PCP) is a private equity firm operating in Southeast Europe, with a primary focus on investments in healthcare companies across Croatia and neighboring countries such as Slovenia.
Oaklins’ team in Croatia was mandated as the sell-side advisor to the seller.
Contáctese con el equipo de la transacción
Transacciones relacionadas
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Ver másbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Ver másBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Ver más